Related Experiment Video
Updated: Jun 26, 2026

Impact of Common Fruit Juices and Toothbrushing on the Discoloration of Primary Teeth
Published on: March 27, 2026
In vitro interactions with repeated grapefruit juice administration--to peel or not to peel?
Shlomo Brill1, Christian Zimmermann, Karin Berger
1Department of Clinical Pharmacology & Toxicology, University Clinic Basel, Basel, Switzerland.
Abstract:
Interactions of acutely administered grapefruit juice (GFJ) with cytochrome P450 isoform 3A4 (CYP3A4) and P-glycoprotein (Pgp) function are well established. In this study, we investigated in vitro the effect of repeated administration of GFJ and its major constituents (the flavonoid naringin, its aglycone naringenin and the furanocoumarin bergamottin) on mRNA expression of MDR1 and CYP3A4 in LS180 cells. Since the bergamottin content is higher in the peel than in the fruit, we compared GFJ containing peel (GFJP+) with juice without any peel extract (GFJP-). GFJP- (1%) showed no significant effect on MDR1 and CYP3A4 mRNA expression, whereas 1% GFJP+ increased expression of MDR1 3.7-fold (P<0.01) and CYP3A4 2.3-fold (P<0.05). Of the tested constituents, only 10 microM bergamottin and 200 microM naringenin induced MDR1 mRNA levels 2.9- and 4.0-fold, respectively (P<0.01 for both), and CYP3A4 mRNA levels 3.2- and 15.6-fold (P<0.01 for both), respectively. Western blot analysis and rhodamine 123 uptake experiments partly confirmed these findings on the protein and the functional level. In summary, GFJ containing no peel extract may have a lower potential for interactions with CYP3A4 or P-glycoprotein.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Fruit Development, Structure, and Function
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Pharmacokinetics: Drug–Drug Interactions
Phase II Reactions: Glucuronidation
Factors Influencing Bioavailability: First-Pass Elimination
